A. Adults & Young People >12
The new guidance recommends SABA-free pathways to reduce the risk of SABA-associated overuse. These include:
- Anti-inflammatory relievers (PRN – In November 2024, the only product licensed for as-needed AIR therapy contained budesonide w/ formoterol)
- MART regime.
The independent guideline committee looked at evidence which showed using the combined ICS and formoterol inhalers when required led to people suffering fewer severe asthma attacks compared to SABA use. Patients who require their AIR therapy three or more times a week should be changed to MART.
